BLSM (BlossomHill Therapeutics) Total Stockholders Equity: $-131.73 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics Total Stockholders Equity?

BlossomHill Therapeutics BLSM +0.12% 8 Total Stockholders Equity is $-131.73 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

BlossomHill Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-131.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BlossomHill Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $-4.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BlossomHill Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2025 was -0.17.

BlossomHill Therapeutics  (NAS:BLSM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BlossomHill Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-131.728-0)/29.081
=-4.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BlossomHill Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.005 + 22.393) / -131.728
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Total Stockholders Equity Related Terms

BlossomHill Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Total Stockholders Equity Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Total Stockholders Equity
-72.88 -131.73

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Total Stockholders Equity -72.88 -131.73
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-131.73 Mil mean?
BlossomHill Therapeutics (BLSM) has a Total Stockholders Equity of $-131.73 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Total Stockholders Equity too high?
BlossomHill Therapeutics' current Total Stockholders Equity is $-131.73 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Total Stockholders Equity compare to ?
BlossomHill Therapeutics' Total Stockholders Equity of $-131.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Total Stockholders Equity is $-131.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Total Stockholders Equity of $-131.73 Mil. The current Total Stockholders Equity is $-131.73 Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Total Stockholders Equity is $-131.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price